Dicerna to pay $27M to settle Alnylam trade secrets lawsuit By: Boston Business Journal via Business Journals April 20, 2018 at 14:20 PM EDT The Cambridge biotechs are both developing RNA interference drugs, which are designed to silence disease-causing genes. Read More >>
